RxDoctor Payments DataLook up a doctor →

Enrique Hernandez Vila, MD

Interventional Cardiology · Ponce, PRNPI 1700044617

Payments from drug & device makers

$44,377in general payments, 2019–2025

Across 470 payments — averaging $94.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$12K
  • Abbott$7K
  • Penumbra, Inc.$5K
  • Cook Incorporated$4K
  • Cardiovascular Systems Inc.$3K
  • Cook Medical LLC$2K
  • plus $11K from 36 others

What the payments were for

  • Consulting fees$6882%
  • Speaking & faculty fees$12,40528%
  • Travel & lodging$8,08018%
  • Food & beverage$23,09852%
  • Education$1070%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,377 in reported general payments places this provider in the 75th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$414,043
Medicare patients
469
Services billed
1,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban177$130,221
EliquisApixaban74$55,199
EntrestoSacubitril/Valsartan44$31,488
BrilintaTicagrelor28$19,189
FarxigaDapagliflozin Propanediol14$10,221
Metoprolol Succinate142$1,331
Cilostazol66$1,259
Labetalol Hcl34$1,002
ClopidogrelClopidogrel Bisulfate83$687
Atorvastatin Calcium84$671
Olmesartan Medoxomil17$572
Colchicine12$417
Valsartan18$408
Losartan Potassium59$364
Carvedilol52$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$504$130,221177 claims
PfizerEliquis$301$55,19974 claims
NovartisEntresto$896$31,48844 claims
AstraZenecaBrilinta, Farxiga$399$29,41042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →